FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2025 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2025”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of January 2025 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 4,388m
• Biotech/Pharma received 53% of the total investment volume (EUR 2,321m) with immunology being the leading indication (27%)
• In January Truveta secured the highest transaction volume with EUR 307m, followed by Kardigan with EUR 288m and Innovaccer with EUR 264m
• Accelmed (United States) is the most active investor (by deal volume in 2025), followed by Y Combinator (United States) and F-Prime Capital (United States)

To access the full report, please click here.